seladelpar
Selected indexed studies
- A Phase 3 Trial of Seladelpar in Primary Biliary Cholangitis. (N Engl J Med, 2024) [PMID:38381664]
- Seladelpar. (, 2012) [PMID:39401310]
- Seladelpar treatment reduces IL-31 and pruritus in patients with primary biliary cholangitis. (Hepatology, 2024) [PMID:38117036]
_Worker-drafted node — pending editorial review._
Connections
seladelpar is a side effect of
Sources
- A Phase 3 Trial of Seladelpar in Primary Biliary Cholangitis. (2024) pubmed
- Seladelpar. (2012) pubmed
- Seladelpar treatment reduces IL-31 and pruritus in patients with primary biliary cholangitis. (2024) pubmed
- Seladelpar: First Approval. (2024) pubmed
- Seladelpar efficacy and safety at 3 months in patients with primary biliary cholangitis: ENHANCE, a phase 3, randomized, placebo-controlled study. (2023) pubmed
- Seladelpar Lysine. (2025) pubmed
- Seladelpar for the Treatment of Primary Biliary Cholangitis. (2025) pubmed
- The role of Seladelpar in primary biliary cholangitis: a systematic review and meta-analysis. (2025) pubmed
- Long-Term Efficacy and Safety of Selective PPARδ Agonist Seladelpar in Primary Biliary Cholangitis: ASSURE Interim Study Results. (2025) pubmed
- Seladelpar: a comprehensive review of its clinical efficacy and safety in the treatment of primary biliary cholangitis. (2025) pubmed